Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials.

Safia Chatur et al.PubMed ↗Full text ↗Publisher ↗

A secondary analysis of NCT01032629. The trial’s primary report, PMID 28605608, speaks for it on the map; the numbers here are shown and do not vote.

What the trial testedas reported · 1,264 people · 2025

Not counted

Reduced cardiovascular events

−36%−42% to −30%

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.64, 95% CI 0.58–0.70

One number in the abstract

the abstract, start to end

… similar observed treatment effect (HR 0.64; 95% CI 0.58-0.70).

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

HR 0.640.58–0.70

AntihypertensivesCardiovascular events

1 / 3

2 papers cite it

2025

2026

this papercites it

2 trials

NCT01032629phase 34,330 enrolled2009a later paper about it NCT02065791phase 34,401 enrolled2014